The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metastasis

Basit Öğe Kaydı
dc.contributor.authorMurtaja, Ahmed
dc.contributor.authorEyol, Ergul
dc.contributor.authorJiang Xiaoqi
dc.contributor.authorBerger, Martin R.
dc.contributor.authorAdwan, Hassan
dc.date.accessioned2024-08-04T20:44:09Z
dc.date.available2024-08-04T20:44:09Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPancreatic ductal adenocarcinoma (PDAC) has one of the poorest prognoses of all malignancy types. To improve the survival of patients with PDAC, the development of novel anticancer agents is warranted. Riproximin (Rpx) is a newly identified plant lectin, which was isolated from Ximenia americana. The ribosome inactivating protein of type II exhibits potent anticancer activity as recently demonstrated. The rat PDAC cell line ASML was used for in vitro and in vivo studies. The antiproliferative effect of Rpx was assessed using an MTT assay. The modulation of proteins involved in apoptosis was evaluated using western blotting. Tumor-bearing nude rats were treated with Rpx, gemcitabine (GEM) or dinaline (DIN) as single agents, or a combination of Rpx with GEM, or DIN. Rpx was administered intraperitoneally at doses of 1.7-5.4 mu g/kg, three times/week, GEM was administered intravenously (50 mg/kg/week) and DIN perorally (10 mg/kg, 5 times/week). Rpx'inhibited ASML cell proliferation at IC50-values of 0.8-172 pM, caused apoptosis and reduced tumor growth significantly by 90% (P<0.05). The survival rate of rats was significantly increased (21.8 days for Rpx treated vs. 17.6 days for control rats; P=0.05). Higher doses of Rpx caused no further reduction in tumor size when compared with the low dose of Rpx or a combination of Rpx with GEM, or DIN. The standard drug GEM alone was less effective compared with Rpx. In addition, DIN was ineffective, and in combination, reduced the activity of Rpx. These results suggest that Rpx has an evident potential for use in pancreatic cancer treatment. Further experiments are required in order to elucidate its affinity for certain cancer cells and to optimize the combination therapy with other antineoplastic agents.en_US
dc.identifier.doi10.3892/ol.2017.7526
dc.identifier.endpage1448en_US
dc.identifier.issn1792-1074
dc.identifier.issn1792-1082
dc.identifier.issue2en_US
dc.identifier.pmid29434835en_US
dc.identifier.scopus2-s2.0-85038413906en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1441en_US
dc.identifier.urihttps://doi.org/10.3892/ol.2017.7526
dc.identifier.urihttps://hdl.handle.net/11616/98066
dc.identifier.volume15en_US
dc.identifier.wosWOS:000426145000010en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpandidos Publ Ltden_US
dc.relation.ispartofOncology Lettersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectpancreatic cancer treatmenten_US
dc.subjectASML cell lineen_US
dc.subjectlectinen_US
dc.subjectXimenia americanaen_US
dc.titleThe ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metastasisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu